Donor T cells and treatment responses in chronic graft-versus-host disease
Defining the T Cell Mediators of Clinical Response in Chronic GVHD
This project looks at how donor T cells and immune signals affect people who develop chronic graft-versus-host disease after an allogeneic stem cell transplant.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11174480 on NIH RePORTER |
What this research studies
As a patient with cGVHD, this work would explain how doctors are studying my donor T cells in blood and tissues to see which immune pathways drive disease and recovery. The team collects samples early after transplant (around Day +100) and follows how T cells change over time and with different treatments. They will compare people who respond well to therapy with those who do not to find immune signatures tied to success or failure. The findings aim to point toward more personalized treatment choices based on each patient's immune profile.
Who could benefit from this research
Good fit: Ideal candidates are people who received an allogeneic hematopoietic stem cell transplant and either have cGVHD or are being monitored around Day +100 after transplant.
Not a fit: People who have not had an allogeneic stem cell transplant or who need immediate clinical therapy rather than contributing to research are unlikely to benefit directly from participation.
Why it matters
Potential benefit: If successful, the work could help predict who is at risk for cGVHD and guide more personalized treatments based on a patient's immune profile.
How similar studies have performed: Mouse models and some patient immune-profiling studies have identified pathways and led to new therapies, but reliably predicting individual treatment response remains largely unproven and this integrated profiling approach is relatively novel.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Kean, Leslie S — Dana-Farber Cancer Inst
- Study coordinator: Kean, Leslie S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.